We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

MP BIOMEDICALS LLC

MP Biomedicals manufactures and sells a comprehensive line of in-vitro diagnostics solutions to hospitals and clinica... read more Featured Products: More products

Download Mobile App




Parkinson’s Disease Patients Have More Inflammatory Bacteria in Their Noses

By LabMedica International staff writers
Posted on 29 Dec 2021
Parkinson’s disease (PD) is a complex neurodegenerative disease characterized by nigrostriatal degeneration resulting in bradykinesia, rigidity, tremor, and gait dysfunction. More...
Non-motor symptoms are also typically present, including depression, constipation, and alteration of smell. Diminished sense of smell (hyposmia), is a common hallmark of prodromal PD.

PD gut dysbiosis is characterized by increased putative pro-inflammatory microbes, belonging to the phylum Proteobacteria, and a reduction in putative beneficial short chain fatty acids (SCFAs)-producing bacteria. Given the loss of olfaction that has been associated with pre-motor PD in 75%–95% of early cases, the nasal cavity may be a secondary site (in addition to the gut) triggering neuroinflammation in PD.

Medical Scientists at the Rush University Medical Center (Chicago, IL, USA) analyzed bacteria in the deep nasal sinus cavity of 30 people with Parkinson’s. The team noted that the deep nasal sinus cavity, far up in the nose, is close to the olfactory bulb, a brain structure involved in the sense of smell. The team also analyzed bacteria in the deep nasal sinus cavities of 11 of the patients’ spouses who did not have Parkinson’s. Spouses were chosen in order to account for environmental factors (e.g., bacteria that happen to live in a person’s house). Bacteria from 17 non-spousal healthy controls also were analyzed.

The scientists used deep nasal swabbing under nasal anterior endoscopy by a trained rhinologist. Total genomic DNA was extracted from the swabs using the FastDNA Spin Kit for Soil (MP Biomedicals, Santa Ana, CA, USA). PCR amplified and sequenced on an Illumina MiniSeq sequencer (Illumina, San Diego, CA, USA). 16S rRNA gene amplicon library preparation was performed using two parallel techniques. To provide superior resolution at the species taxonomic level, a multi-amplicon workflow was conducted employing the Swift Amplicon 16S + ITS Panel (Swift Biosciences, Madison, WI, USA).

The investigators reported that, compared to the controls, people with Parkinson’s tended to have higher amounts of certain bacteria that are likely to have pro-inflammatory effects. For example, many patients had high abundances of Moraxella catarrhalis, which is known to be an opportunistic pathogen, a bacteria that usually does not cause disease, but can under certain circumstances. The team noted that M. catarrhalis was not always linked with Parkinson’s. indeed, some patients had no detectable amounts of this type of bacteria. But microbiomes with the highest abundances of these bacteria consistently came from people with Parkinson’s. In addition to high levels of pro-inflammatory bacteria, Parkinson’s patients also tended to have lower amounts of bacteria with anti-inflammatory properties, including Blautia wexlerae, Lachnospira pectinoschiza, and Propionibacterium humerusii.

The authors concluded that their data indicated the presence of a dysbiotic and potentially pro-inflammatory deep nasal sinus cavity microbiota environment in PD subjects as compared to control subjects. Within PD subjects there was a positive correlation between putative pro-inflammatory bacteria, including M. catarrhalis, and PD clinical features. The study was published on December 8, 2021 in the journal npj Parkinson’s Disease.

Related Links:
Rush University Medical Center
MP Biomedicals
Illumina
Swift Biosciences



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.